JPH11512087A5 - - Google Patents

Info

Publication number
JPH11512087A5
JPH11512087A5 JP1997509499A JP50949997A JPH11512087A5 JP H11512087 A5 JPH11512087 A5 JP H11512087A5 JP 1997509499 A JP1997509499 A JP 1997509499A JP 50949997 A JP50949997 A JP 50949997A JP H11512087 A5 JPH11512087 A5 JP H11512087A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997509499A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11512087A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1996/013286 external-priority patent/WO1997007214A1/en
Publication of JPH11512087A publication Critical patent/JPH11512087A/ja
Publication of JPH11512087A5 publication Critical patent/JPH11512087A5/ja
Withdrawn legal-status Critical Current

Links

JP9509499A 1995-08-18 1996-08-16 ヒトの病理学及び生理学における、アドレノメジュリン(am)及び遺伝子関連産物(pamp)の機能的役割 Withdrawn JPH11512087A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US251495P 1995-08-18 1995-08-18
US60/002,514 1995-08-18
US293695P 1995-08-30 1995-08-30
US60/002,936 1995-08-30
US1317296P 1996-03-12 1996-03-12
US60/013,172 1996-03-12
PCT/US1996/013286 WO1997007214A1 (en) 1995-08-18 1996-08-16 Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006349430A Division JP4077861B2 (ja) 1995-08-18 2006-12-26 ヒトの病理学及び生理学における、アドレノメジュリン(am)及び遺伝子関連産物(pamp)の機能的役割

Publications (2)

Publication Number Publication Date
JPH11512087A JPH11512087A (ja) 1999-10-19
JPH11512087A5 true JPH11512087A5 (enExample) 2004-09-09

Family

ID=27357180

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9509499A Withdrawn JPH11512087A (ja) 1995-08-18 1996-08-16 ヒトの病理学及び生理学における、アドレノメジュリン(am)及び遺伝子関連産物(pamp)の機能的役割
JP2006349430A Expired - Fee Related JP4077861B2 (ja) 1995-08-18 2006-12-26 ヒトの病理学及び生理学における、アドレノメジュリン(am)及び遺伝子関連産物(pamp)の機能的役割

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006349430A Expired - Fee Related JP4077861B2 (ja) 1995-08-18 2006-12-26 ヒトの病理学及び生理学における、アドレノメジュリン(am)及び遺伝子関連産物(pamp)の機能的役割

Country Status (7)

Country Link
US (4) US6320022B1 (enExample)
EP (1) EP0845036B1 (enExample)
JP (2) JPH11512087A (enExample)
AT (1) ATE180832T1 (enExample)
CA (1) CA2229741C (enExample)
DE (1) DE69602756T2 (enExample)
WO (1) WO1997007214A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440421B1 (en) 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5888963A (en) * 1996-04-18 1999-03-30 Auckland Uniservices Limited Treatment of bone disorders with adrenomedullin
US6869926B1 (en) 1997-09-26 2005-03-22 Auckland Uniservices Limited Therapeutic method
EP1214600B1 (en) 1999-09-10 2005-12-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Determination of adrenomedullin-binding proteins
KR100486622B1 (ko) * 2000-11-17 2005-05-03 차국헌 폴리메틸실세스퀴옥산 공중합체와 그 제조방법 및 이를이용한 저유전성 코팅막
FR2821080B1 (fr) * 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
US20110087312A1 (en) * 2001-03-02 2011-04-14 Erchonia Corporatin Method for Treatment of Diabetes and Prediabetes with Low-Level Laser Therapy
JP2005508838A (ja) 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CN1753909A (zh) * 2002-03-19 2006-03-29 株式会社康福来 肽,含有该肽的药物组合物和用于治疗癌症的药物组合物
US20040127445A1 (en) * 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
CN100434439C (zh) * 2002-09-30 2008-11-19 肿瘤疗法科学股份有限公司 与人髓细胞白血病相关的基因和多肽
EP1575417A4 (en) * 2002-09-30 2007-07-04 Bayer Pharmaceuticals Corp CANCER FORECASTING AND PROGNOSTIC TECHNIQUES AND SURVEILLANCE OF ANTICANCER THERAPY
AU2003282660C1 (en) 2002-10-04 2009-04-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vasoregulating compounds and methods of their use
EP1575511A4 (en) * 2002-11-07 2006-06-28 Us Gov Health & Human Serv NEW TARGET FOR ANGIOGENESIS AND ANTI-ANGIOGENESIS THERAPY
AU2004225437B2 (en) * 2003-03-28 2010-05-13 Cancer Advances, Inc. Gastrin hormone immunoassays
US7228658B2 (en) 2003-08-27 2007-06-12 Weyerhaeuser Company Method of attaching an end seal to manufactured seeds
CA2788502A1 (en) * 2003-09-08 2005-03-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Non-peptide agonists and antagonists of adrenomedullin and gastric releasing peptide
US8691575B2 (en) * 2003-09-30 2014-04-08 Weyerhaeuser Nr Company General method of classifying plant embryos using a generalized Lorenz-Bayes classifier
US20050108935A1 (en) * 2003-11-25 2005-05-26 Edwin Hirahara Method and system of manufacturing artificial seed coats
CA2484533C (en) * 2003-11-25 2008-12-02 Weyerhaeuser Company Systems and method of embryo delivery for manufactured seeds
US20050108929A1 (en) * 2003-11-25 2005-05-26 Edwin Hirahara Method and system for creating manufactured seeds
CA2486289C (en) * 2003-11-25 2008-01-08 Weyerhaeuser Company Combination end seal and restraint
US7555865B2 (en) * 2003-11-25 2009-07-07 Weyerhaeuser Nr Company Method and system of manufacturing artificial seed coats
US7356965B2 (en) * 2003-12-11 2008-04-15 Weyerhaeuser Co. Multi-embryo manufactured seed
US7591287B2 (en) * 2003-12-18 2009-09-22 Weyerhaeuser Nr Company System and method for filling a seedcoat with a liquid to a selected level
US7568309B2 (en) * 2004-06-30 2009-08-04 Weyerhaeuser Nr Company Method and system for producing manufactured seeds
ES2400058T3 (es) 2004-09-22 2013-04-05 Cancer Advances, Inc. Anticuerpos monoclonales para progastrina
CA2518279A1 (en) * 2004-09-27 2006-03-27 Weyerhaeuser Company Manufactured seed having a live end seal coating
US20060070145A1 (en) * 2004-09-27 2006-03-30 Carlson William C Manufactured seed having a live end seal
US7547488B2 (en) * 2004-12-15 2009-06-16 Weyerhaeuser Nr Company Oriented strand board panel having improved strand alignment and a method for making the same
US7654037B2 (en) * 2005-06-30 2010-02-02 Weyerhaeuser Nr Company Method to improve plant somatic embryo germination from manufactured seed
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
US9829494B2 (en) * 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
DE102006052916A1 (de) * 2006-11-08 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM
AU2008303956A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Proadrenomedullin alone or in combination with big gastrin I as a therapeutic agent
FR2934597B1 (fr) * 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
US20110262939A1 (en) * 2008-10-31 2011-10-27 B.R.A.H.M.S Gmbh Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
EP2389799A1 (en) * 2010-05-25 2011-11-30 BioMass Booster, S.L. Method for increasing plant biomass
CN103109192A (zh) * 2010-06-18 2013-05-15 塞尚公司 用于妊娠性高血压和先兆子痫的预后和风险评估的标志物
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
JP5932279B2 (ja) * 2011-10-07 2016-06-08 ポーラ化成工業株式会社 スクリーニング方法
US8776012B2 (en) * 2011-10-25 2014-07-08 International Business Machines Corporation Automatic scheduling of review meetings
JP6336911B2 (ja) * 2011-11-16 2018-06-06 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング アドレノメジュリンアッセイおよび成熟アドレノメジュリンの測定方法
PT2780370T (pt) 2011-11-16 2019-10-30 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento anticorpo anti-adm ou estrutura de anticorpo anti-adm não ig para utilização na terapia de uma doença aguda ou condição aguda de um paciente para estabilizar a circulação
PT2780371T (pt) 2011-11-16 2019-01-30 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
SG10201801919QA (en) 2011-11-16 2018-04-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
JP5953108B2 (ja) * 2012-05-14 2016-07-20 ポーラ化成工業株式会社 スクリーニング方法
JP6218084B2 (ja) 2012-10-04 2017-10-25 国立研究開発法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
PL3082858T3 (pl) * 2013-12-20 2021-09-27 Angiobiomed Gmbh Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu
DK3067093T3 (da) * 2015-03-12 2019-11-18 Fund Rioja Salud Anvendelse af en inhibitor af adrenomedullin til fremstilling af et lægemiddel egnet til forebyggelse og behandling af sygdomme, der reducerer knogletætheden
US11370822B2 (en) 2017-05-26 2022-06-28 The Governors Of The University Of Alberta Self-assembling peptide for activating human mast cells
AU2018283284B2 (en) 2017-06-15 2024-05-16 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
EP3438668A1 (en) * 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections
EP3971573A1 (en) 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
EP3502706A1 (en) 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
EP4058466A1 (en) 2019-11-13 2022-09-21 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
WO1994025482A1 (en) * 1993-04-23 1994-11-10 Evans Herbert J Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン

Similar Documents

Publication Publication Date Title
JP2000500033A5 (enExample)
JP2000500445A5 (enExample)
JP2000500440A5 (enExample)
JP2000500327A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500406A5 (enExample)
JPH11512232A5 (enExample)
JP2000500361A5 (enExample)
JP2000500115A5 (enExample)
JPH11512087A5 (enExample)
JP2000500322A5 (enExample)
JP2000500342A5 (enExample)
JP2000500112A5 (enExample)
JP2000500051A5 (enExample)
JP2000500407A5 (enExample)
JP2000500397A5 (enExample)
JPH11507644A5 (enExample)
JP2000502392A5 (enExample)
JP2000500019A5 (enExample)
JPH11510490A5 (enExample)
JP2000500166A5 (enExample)
JPH11510046A5 (enExample)
JP2000500125A5 (enExample)
JP2000500044A5 (enExample)